Adds share move in paragraph 1, details throughout

May 27 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved AbbVie's drug to treat blastic plasmacytoid dendritic cell neoplasm, a very rare type of blood cancer.

AbbVie's shares were up more than 1% in afternoon trading.

The approval provides a new treatment option in a setting with limited choices, particularly for patients whose disease has returned or did not respond to earlier treatment.

The drug, pivekimab sunirine‑pvzy, is given through a vein once every three weeks.

The FDA said the drug carries a boxed warning for serious liver problems, including a condition where blood flow in the liver is blocked.

The agency also flagged risks such as reactions during infusion and fluid buildup in the body.